Xiaobo Lei

InstitutionInstitute of Pathogen Biology
AddressBeijing
China
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 9 Covid-19 publications, with a maximum of 2 publications in February 2021 and April 2021
    All Publications
    Bar chart showing 31 publications over 12 distinct years, with a maximum of 6 publications in 2011 and 2021
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerg Microbes Infect. 2021 Dec; 10(1):1227-1240. PMID: 34057039.
      Citations:    Fields:    Translation:HumansAnimalsCells
    2. Zhao J, Zhang Y, Wang M, Liu Q, Lei X, Wu M, Guo S, Yi D, Li Q, Ma L, Liu Z, Guo F, Wang J, Li X, Wang Y, Cen S. Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp. ACS Infect Dis. 2021 06 11; 7(6):1535-1544. PMID: 34038639.
      Citations: 1     Fields:    Translation:Humans
    3. Wang B, Zhang C, Lei X, Ren L, Zhao Z, Wang J, Huang H. Construction of Non-infectious SARS-CoV-2 Replicons and Their Application in Drug Evaluation. Virol Sin. 2021 Oct; 36(5):890-900. PMID: 33835389.
      Citations: 2     Fields:    Translation:Humans
    4. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. Author Correction: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2021 Apr 01; 12(1):2144. PMID: 33795662.
      Citations: 2     Fields:    
    5. Wang W, Zhou Z, Xiao X, Tian Z, Dong X, Wang C, Li L, Ren L, Lei X, Xiang Z, Wang J. SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Cell Mol Immunol. 2021 04; 18(4):945-953. PMID: 33637958.
      Citations: 16     Fields:    Translation:HumansCells
    6. Li Q, Yi D, Lei X, Zhao J, Zhang Y, Cui X, Xiao X, Jiao T, Dong X, Zhao X, Zeng H, Liang C, Ren L, Guo F, Li X, Wang J, Cen S. Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase. Acta Pharm Sin B. 2021 Jun; 11(6):1555-1567. PMID: 33614402.
      Citations: 5     
    7. Xiao X, Wang C, Wang Y, Dong X, Jiao T, Zhao Z, Ren L, Dela Cruz CS, Sharma L, Lei X, Wang J. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. Front Immunol. 2020; 11:586572. PMID: 33324406.
      Citations: 16     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    8. Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, Wang C, Wang Y, Li L, Ren L, Guo F, Zhao Z, Zhou Z, Xiang Z, Wang J. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020 07 30; 11(1):3810. PMID: 32733001.
      Citations: 235     Fields:    Translation:HumansCellsPHPublic Health
    9. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 03 27; 11(1):1620. PMID: 32221306.
      Citations: 1016     Fields:    Translation:HumansCellsPHPublic Health